Amgen (AMGN) Q4 FY25 earnings call

Amgen concluded FY25 with robust operational performance, driven by double-digit growth in revenues and EPS, and 14 products achieving blockbuster status. The company is entering 2026 with momentum from key growth drivers and a deep pipeline, particularly in cardiometabolic and rare diseases, while navigating anticipated biosimilar competition and regulatory dialogues for certain products. Management remains confident in its ability to deliver sustained long-term growth and value.